Table 5.
Treatments of patients with STAT1 GOF mutations
| Treatment | Patients (%) |
|---|---|
| n = 274 | |
| No antifungal treatment | 19 (7) |
| Intermittent antifungal treatment | 53 (19) |
| Current long-term antifungal treatment | 202 (74) |
| Local treatment only | 8 (3) |
| Oral fluconazole | 150 (55) |
| Oral posaconazole/itraconazole | 53 (19) |
| Oral voriconazole | 19 (7) |
| IV echinocandins | 6 (2) |
| Oral terbinafine | 3 (1) |
| IV amphotericin B | 7 (3) |
| Antibiotic prophylaxis | 66 (24) |
| Co-trimoxazole | 41 (15) |
| Macrolides | 20 (7) |
| Others* | 12 (4) |
| Antiviral prophylaxis | 4 (1) |
| Polyvalent immunoglobulins | 37 (14) |
| Immunotherapy† | 8 (3) |
| Immunosuppressive therapies‡ | 6 (2) |
| Hematopoietic stem cell transplantation (HSCT) | 5 (2) |
*
Nebulized colimycin, topical fucidic acid, fluoroquinolone, tetracycline, amoxicillin.
†
Granulocyte–colony stimulating factor (G-CSF)/granulocyte macrophage–colony stimulating factor (GM-CSF), interferon (IFN)α/γ, rituximab.
‡
Cyclosporine, aziathoprine, corticoids, or mycophenolate mofetil.